Tanya Lewis

CIK: 0001451038

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

DMAC

DiaMedica Therapeutics Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (2 total)

DMAC
DiaMedica Therapeutics Inc.
Jun 1, 2026
Award(A)
Stock Option (right to buy)
Direct
40.4K shares-
DMAC
DiaMedica Therapeutics Inc.
Jun 1, 2025
Award(A)
Stock Option (right to buy)
Direct
32.2K shares-

		Type	Shares	Price		Ownership
Jun 1, 2026	DMAC DiaMedica Therapeutics Inc.	Award(A) Stock Option (right to buy)	40,412	-	-	Direct
Jun 1, 2025	DMAC DiaMedica Therapeutics Inc.	Award(A) Stock Option (right to buy)	32,162	-	-	Direct

1-2 of 2 transactions

About Lewis Tanya

Lewis Tanya (SEC CIK 0001451038) files insider reports with the SEC as Director of DiaMedica Therapeutics Inc. (DMAC).

Signal8 holds 2 ownership filings by Lewis Tanya, all Form 4s, filed between Jun 3, 2025 and Jun 3, 2026. Those filings report 2 transactions, from Jun 1, 2025 to Jun 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Lewis Tanya's filings is in MINNEAPOLIS, MN.

Recent filings by Lewis Tanya

Jun 1, 2026: Grant or award of DMAC derivative securities (Form 4, code A).
Jun 1, 2025: Grant or award of DMAC derivative securities (Form 4, code A).

Other insiders filing for DiaMedica Therapeutics Inc. (DMAC)

How to read Form 4 transaction codes